ECEESPE2025 Poster Presentations Pituitary, Neuroendocrinology and Puberty (162 abstracts)
Insulin-like growth factor 1 as a diagnostic marker to differentiate progressive central precocious puberty from non-progressive precocious puberty: a prospective study
Ana Leite 1,2,3 , Rosa Campos 1 , Maria Rangel 1 , Clara Torres 1 , Filipa Santos 1 , Sónia Aires 1 , Firmino Machado 1,3 , Luís Azevedo 4,5 & Catarina Limbert 6,7
1Unidade Local de Saúde Gaia e Espinho, Vila Nova de Gaia, Portugal; 2Clínica CUF - São João da Madeira, São João da Madeira, Portugal; 3University of Aveiro, Department of Medical Science, Aveiro, Portugal; 4University of Porto, Faculty of Medicine, Department of Comunity Medicine, Information and Health Decisions Sciences (MEDCIDS), Porto, Portugal; 5University of Porto, CINTESIS@RISE - Center for Health Technology and Services Research (CINTESIS) & Health Research Network Associated Laboratory (RISE), Porto, Portugal; 6Unidade Local de Saúde São José - Hospital Dona Estefânia, Lisboa, Portugal; 7NOVA University of Lisbon, NOVA Medical School, Comprehensive Health Research Center (CHRC), Lisbon, Portugal
JOINT616
Background: Central precocious puberty (CPP) results from early activation of the hypothalamic-pituitary-gonadal axis. Its diagnosis often requires GnRH stimulation tests, which are invasive and costly. Serum insulin-like growth factor 1 (IGF1) and IGF1-SDS levels have emerged as potential markers to differentiate CPP from non-progressive forms of CPP (NP-CPP), as isolated thelarche (IT).
Methods: Prospective study (June 2022-December 2024) including 82 girls under 8 years. Participants were divided into CPP (n = 39), non-progressive puberty (NP-CPP and IT, n = 26), and control groups (n = 17). Anthropometric measurements, Tanner staging, bone age, pelvic ultrasound and serum IGF1 and IGF1-SDS levels were performed. GnRH stimulation tests confirmed CPP cases.
Results: Mean serum IGF1 and IGF1-SDS levels were significantly higher in CPP patients (270.15 ng/mL; 1.943 SDS) compared to NP-CPP (174.12 ng/mL; 0.788 SDS) and controls (139.28 ng/mL; 0.208 SDS) (P < 0.001). Multivariate analysis confirmed IGF1 (OR=1.025, 95%CI: 1.010-1.040) and IGF1-SDS (OR=8.721, 95%CI: 2.624-28.986) as significant predictors of CPP. ROC analysis revealed an AUC of 0.837 for IGF1 (95%CI: 0.738-0.935) and 0.862 for IGF1-SDS (95%CI:0.771-0.953). Cut-off values of 231 ng/mL for IGF1 (71.8% sensitivity, 96.2% specificity) and 1.71 for IGF1-SDS (64.1% sensitivity, 96.2% specificity) demonstrated good accuracy (82.2% and 77.8%, respectively).
Conclusions: Serum IGF1 and IGF1-SDS are promising as effective non-invasive markers to distinguish CPP from non-progressive precocious puberty. Values below 231 ng/mL or 1.71 SDS may significantly reduce the likelihood of CPP, potentially avoiding invasive GnRH stimulation tests. These findings may support the integration of IGF1 measurements into the initial diagnostic approach for girls presenting with early pubertal signs.
Volume 110
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more